[Immunohistochemical approach to reveal the growth potential of uterine cancers using anti-BrdU antibody and Ki-67].
To reveal the growth potential of uterine cancer, the population of S-phase and proliferating cells were examined with immunohistochemical technique using anti-BrdU antibody and Ki-67. BrdU is a thymidine analogue that is also incorporated into nuclear DNA and S-phase cells are recognized with anti-BrdU antibody. Ki-67 reacts a nuclear antigen present in proliferating cells (late G1, S, M and G2 phase). The percentage of BrdU-labeled cells (labeling index: LI) and that of cells recognized with Ki-67 (growth fraction: GF) were calculated. LI and GF were examined in 12 cervical cancers (LI: 16.0 +/- 6.0; GF: 32.2 +/- 11.2, mean +/- SD), 18 normal ectocervical portions (LI: 6.9 +/- 3.1; GF: 11.4 +/- 5.0), 13 endometrial cancers (LI: 15.9 +/- 5.0; GF: 26.2 +/- 9.0) and 11 normal endometrial tissues (LI: 12.2 +/- 6.1; GF 20.3 +/- 6.8). Indices of GF were always higher than LI in any cases. Both indices of LI and GF in malignant cases were higher than normal cases, therefore, high growth potential of uterine cancer was demonstrated. Both LI and GF of squamous cell carcinoma were higher than adenocarcinoma. In general, the values of GF were parallel to those of LI, and a regression line: Y = 1.44 X + 3.93 (r = 0.80) was obtained. Therefore, S-phase cells occupied about 60-70% of all proliferating cells. These results showed that these two parameters were useful to evaluate growth potential of uterine cancer, but calculation of GF using Ki-67 might be superior to LI using anti-BrdU antibody in terms of simplicity and rapidity.(ABSTRACT TRUNCATED AT 250 WORDS)
Yoshinouchi
M
M
D000230:Adenocarcinoma / Q000473:pathology*; D000911:Antibodies, Monoclonal; D001973:Bromodeoxyuridine / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D002467:Cell Nucleus / Q000276:immunology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008940:Mitotic Index; D002583:Uterine Cervical Neoplasms / Q000473:pathology*; D014594:Uterine Neoplasms / Q000473:pathology*
D000911:Antibodies, Monoclonal; D001973:Bromodeoxyuridine